YH14618 + YH14618 + YH14618 + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Degenerative Disc Disease

Conditions

Degenerative Disc Disease

Trial Timeline

May 1, 2012 → Jul 1, 2014

About YH14618 + YH14618 + YH14618 + Placebo

YH14618 + YH14618 + YH14618 + Placebo is a phase 1/2 stage product being developed by Yuhan for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01526330. Target conditions include Degenerative Disc Disease.

What happened to similar drugs?

1 of 6 similar drugs in Degenerative Disc Disease were approved

Approved (1) Terminated (1) Active (4)
PimavanserinAcadia PharmaceuticalsApproved
LatozinemabAlectorPhase 3
🔄Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3
🔄PimavanserinAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01526330Phase 1/2Completed